The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials-Reference-Cited by-同舟云学术

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials

Published:2017-12-06 Issue:6 Volume:124 Page:1197-1206
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

de Koning Harry J.¹,Gulati Roman²^ORCID,Moss Sue M.³,Hugosson Jonas⁴,Pinsky Paul F.⁵,Berg Christine D.⁶,Auvinen Anssi⁷,Andriole Gerald L.⁸,Roobol Monique J.⁹,Crawford E. David¹⁰,Nelen Vera¹¹,Kwiatkowski Maciej¹²,Zappa Marco¹³,Luján Marcos¹⁴,Villers Arnauld¹⁵,de Carvalho Tiago M.¹^ORCID,Feuer Eric J.¹⁶,Tsodikov Alex¹⁷,Mariotto Angela B.¹⁶,Heijnsdijk Eveline A. M.¹^ORCID,Etzioni Ruth²

Affiliation:

1. Department of Public Health; Erasmus Medical Center; Rotterdam the Netherlands

2. Division of Public Health Sciences; Fred Hutchinson Cancer Research Institute; Seattle Washington

3. Wolfson Institute; Queen Mary University of London; London United Kingdom

4. Department of Urology; Sahlgrenska University Hospital; Goteborg Sweden

5. Division of Cancer Prevention, National Cancer Institute; Bethesda Maryland

6. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine; Baltimore Maryland

7. School of Health Sciences; University of Tampere; Tampere Finland

8. Division of Urologic Surgery, Department of Surgery; Washington University School of Medicine; St. Louis Missouri

9. Department of Urology; Erasmus Medical Center; Rotterdam the Netherlands

10. Urologic Oncology; University of Colorado; Denver Colorado

11. Provinciaal Instituut voor Hygiene; Antwerp Belgium

12. Department of Urology; Aarau Canton Hospital; Aarau Switzerland

13. Unit of Epidemiology, Institute for Cancer Prevention; Florence Italy

14. Urology Service, Infanta Cristina University Hospital; Complutense University of Madrid; Parla Madrid Spain

15. Department of Urology; Regional University Hospital Center; Lille France

16. Division of Cancer Control and Population Sciences, National Cancer Institute; Bethesda Maryland

17. Department of Biostatistics; University of Michigan; Ann Arbor Michigan

Funder

National Cancer Institute

Cancer Intervention and Surveillance Modeling Network (CISNET)

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference32 articles.

1. Screening and prostate-cancer mortality in a randomized European study;Schroder;N Engl J Med,2009

2. Prostate-cancer mortality at 11 years of follow-up;Schroder;N Engl J Med,2012

3. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up;Schroder;Lancet,2014

4. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up;Andriole;J Natl Cancer Inst,2012

5. Screening for prostate cancer-the controversy that refuses to die;Barry;N Engl J Med,2009

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer;Annals of Internal Medicine;2024-07

2. Transcriptome-wide association analysis identifies candidate susceptibility genes for prostate-specific antigen levels in men without prostate cancer;Human Genetics and Genomics Advances;2024-07

3. Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer;BJU International;2024-05-09

4. Development and validation of an imageless machine‐learning algorithm for the initial screening of prostate cancer;The Prostate;2024-04-04

5. Exploring the relation of active surveillance schedules and prostate cancer mortality;Cancer Medicine;2024-03